Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 4/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.33 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4052805 | 0.93 | LTB4R (0.46) | LTB4RPDE10ACYSLTR2CYSLTR1ALOX5AP | |
| SCHEMBL7801372 | 0.89 | LTB4R (0.43) | LTB4RPDE10ACYSLTR2CYSLTR1ALOX5AP | |
| SCHEMBL4237247 | 0.86 | LTB4R (0.37) | LTB4RPDE10AP2RX7CYSLTR2CYSLTR1 | |
| SCHEMBL13765233 | 0.85 | PDE10A (0.39) | LTB4RPDE10ACYSLTR2CYSLTR1ALOX5AP | |
| SCHEMBL4229150 | 0.85 | LTB4R (0.36) | LTB4RCYSLTR2CYSLTR1ALOX5AP | |
| SCHEMBL7808129 | 0.83 | LTB4R (0.38) | LTB4RCYSLTR2CYSLTR1ALOX5AP | |
| SCHEMBL13765183 | 0.83 | CYSLTR2 (0.35) | LTB4RCYSLTR2CYSLTR1ALOX5AP | |
| SCHEMBL4230433 | 0.82 | TBXAS1 (0.37) | LTB4RCYSLTR2CYSLTR1ALOX5AP | |
| SCHEMBL7806836 | 0.82 | LTB4R (0.38) | LTB4RCYSLTR2CYSLTR1ALOX5AP | |
| SCHEMBL4376492 | 0.82 | CYSLTR2 (0.38) | LTB4RCYSLTR2CYSLTR1ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557212-B2 | Tricyclic derivatives as LTD4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-07-07 | — | — | US | disclosed |
| US-7557212-B2 | Tricyclic derivatives as LTD4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-07-07 | — | — | US | disclosed |
| US-7557212-B2 | Tricyclic derivatives as LTD4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-07-07 | — | — | US | disclosed |
| EP-1560834-B1 | NEW TRICYCLIC DERIVATIVES AS LTD4 ANTAGONISTS | ALMIRALL LAB (ES) | 2008-06-25 | — | — | EP | disclosed |
| EP-1560834-B1 | NEW TRICYCLIC DERIVATIVES AS LTD4 ANTAGONISTS | ALMIRALL LAB (ES) | 2008-06-25 | — | — | EP | disclosed |
| US-20060116363-A1 | Tricyclic derivatives as ltd4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116363-A1 | Tricyclic derivatives as ltd4 antagonists | LTA4H, LTC4S, LTB4R2 | LTB4R 4/4885PDE10A 2198/4885P2RX7 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.